BeStock  
Stocks › Biotechnology › BMRN

Biomarin Pharmaceutical BMRN

US equityMarket cap rank #1288Biotechnology
$60.41 −$1.01 (-1.64%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $60.02 -0.65%
Open$61.53
Prev close$61.42
Day range$59.84 – $62.01
Volume6.06M
Market cap$11.70B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$1.02B+32.0% YoY
Operating profit$205.65M+18.0% YoY
Net profit-$122.83M-299.5% YoY
Diluted EPS-$0.63-293.8% YoY
Free cash flow$164.16M-51.0% YoY
Operating cash flow$188.21M

Revenue, last 8 quarters

$747.3MDec '24$745.1MMar '25$825.4MJun '25$776.1MSep '25$874.6MDec '25$766.2MMar '26$989.7MJun '26$1.0BSep '26

Net profit, last 8 quarters

$124.9MDec '24$185.7MMar '25$240.5MJun '25$-30.7MSep '25$-46.6MDec '25$105.5MMar '26$44.8MJun '26$-122.8MSep '26

Diluted EPS by quarter

0.64Dec '240.95Mar '251.23Jun '25-0.16Sep '25-0.24Dec '250.54Mar '260.23Jun '26-0.63Sep '26

Free cash flow by quarter

$165.3MDec '24$157.6MMar '25$167.9MJun '25$334.9MSep '25$56.6MDec '25$199.7MMar '26$133.9MJun '26$164.2MSep '26

Annual revenue

$1.9BFY20$1.8BFY21$2.1BFY22$2.4BFY23$2.9BFY24$3.2BFY25

Profitability & balance sheet

Gross margin76.0%
Operating margin4.9%
Net margin-0.5%
Return on equity-0.3%
Return on assets-0.2%
Return on invested capital0.3%
Current ratio2.44
Liabilities / assets45.9%
Cash & investments$736.01M
Total debt$4.17B
Net cash (debt)-$3.44B
Free cash flow / sales15.2%

Where the revenue comes from

Quarter 2026/Q3

By business line

  • Voxzogo$245.01M 23.9%
  • Vimizim$215.80M 21.1%
  • GALAFOLD$151.83M 14.8%
  • Palynziq$111.04M 10.8%
  • Naglazyme$107.82M 10.5%
  • ALDURAZYME$56.60M 5.5%
  • Brineura$52.71M 5.1%
  • POMBILITI + OPFOLDA$48.59M 4.7%
  • Kuvan$22.95M 2.2%
  • Other$12.30M 1.2%

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $1.02B $989.71M $766.21M $3.22B $874.57M
Total Operating Revenue $1.02B $989.71M $766.21M $3.22B $874.57M
Cost of Revenue $205.42M $202.80M $195.00M $717.44M $275.71M
Gross Profit $819.23M $786.91M $571.21M $2.50B $598.86M
Operating Expense $613.58M $675.94M $441.58M $2.09B $864.42M
Selling and Admin Expenses $333.60M $395.50M $258.30M $1.15B $446.20M
-Selling & Marketing Expense $148.90M $142.20M $124.90M $530.20M $174.20M
-General & Admin Expense $184.70M $253.30M $133.40M $622.80M $272.00M
Research & Development $180.53M $206.95M $178.80M $921.93M $413.38M
Depreciation & Amortization & Depletion $99.46M $73.49M $4.48M $19.39M $4.85M
-Depreciation & Amortization $99.46M $73.49M $4.48M $19.39M $4.85M
Operating Profit $205.65M $110.97M $129.63M $409.50M -$265.57M
Net Non-Operating Interest Income (Expense) -$51.00M -$52.82M $7.60M $64.01M $16.43M
Non-Operating Interest Income $4.63M $10.48M $22.56M $74.90M $19.21M
Non-Operating Interest Expense $55.63M $63.30M $14.96M $10.90M $2.78M
Other Income (Expense) -$286.38M $3.28M $3.96M $9.00M $221.99M
Special Income (Charges) -$287.69M – – $0.00 $220.96M
-Less:Other Special Charges $287.69M – – – –
Other Non-Operating Income (Expenses) $1.31M $3.28M $3.96M $9.00M $1.03M
Pretax Profit -$131.77M $61.38M $141.20M $482.48M -$27.15M
Tax -$8.94M $16.62M $35.68M $133.58M $19.42M
Net Profit -$122.83M $44.76M $105.53M $348.90M -$46.57M
Profit from Continuing Operations -$122.83M $44.76M $105.53M $348.90M -$46.57M
Net Income to Parent Company -$122.83M $44.76M $105.53M $348.90M -$46.57M
Net Income to Common Stockholders -$122.83M $44.76M $105.53M $348.90M -$46.57M
Basic EPS -$0.63 $0.23 $0.55 $1.82 -$0.24
Diluted EPS -$0.63 $0.23 $0.54 $1.80 -$0.24
-Gain on Sale of Property/Plant/Equipment – – – $0.00 $0.00

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $11.57B $11.72B $8.59B $7.59B $7.59B
Total Current Assets $3.92B $3.97B $4.61B $3.95B $3.95B
Cash and Cash Equivalents & Short-Term Investments $736.01M $874.01M $2.22B $1.56B $1.56B
-Cash and Cash Equivalents $736.01M $874.01M $2.22B $1.31B $1.31B
-Short Term Investments $0.00 $0.00 $0.00 $248.93M $248.93M
Receivables $1.08B $1.06B $903.91M $908.21M $908.21M
-Accounts Receivable $1.08B $1.06B $903.91M $908.21M $908.21M
Inventory $1.80B $1.78B $1.27B $1.30B $1.30B
Other Current Assets $312.21M $254.05M $205.50M $185.78M $185.78M
Total Non-Current Assets $7.65B $7.75B $3.99B $3.64B $3.64B
Net PPE $980.08M $989.99M $958.07M $952.51M $952.51M
-Gross PPE $2.11B $2.10B $2.05B $2.03B $2.03B
-Accumulated Depreciation -$1.13B -$1.11B -$1.09B -$1.07B -$1.07B
Investments and Advances $0.00 $0.00 $0.00 $492.24M $492.24M
Goodwill and Other Intangible Assets $5.44B $5.54B $400.86M $410.04M $410.04M
-Goodwill $666.37M $655.75M $196.20M $196.20M $196.20M
-Other Intangible Assets $4.78B $4.88B $204.66M $213.84M $213.84M
Non-Current Deferred Assets $897.79M $888.58M $1.50B $1.51B $1.51B
Other Non-Current Assets $327.11M $338.14M $1.13B $277.05M $277.05M
Total Liabilities $5.31B $5.40B $2.38B $1.51B $1.51B
Total Current Liabilities $1.60B $1.66B $793.15M $759.03M $759.03M
Payables $385.38M $675.14M $582.79M $491.33M $491.33M
-Accounts Payable $130.72M $406.98M $395.47M $312.77M $312.77M
-Total Tax Payable $18.92M $9.14M $3.01M $3.67M $3.67M
-Other Payable $235.74M $259.03M $184.31M $174.89M $174.89M
Current Accrued Expenses $509.78M $60.56M $16.75M $8.59M $8.59M
Short-Term Debt and Capital Lease Obligation $675.24M $674.26M $9.32M $8.69M $8.69M
-Current Debt $658.72M $658.20M – – –
-Current Capital Lease Obligation $16.52M $16.06M $9.32M $8.69M $8.69M
Other Current Liabilities $34.43M $33.53M $31.68M $31.01M $31.01M
Total Non-Current Liabilities $3.71B $3.74B $1.59B $747.99M $747.99M
Long Term Debt and Capital Lease Obligation $3.51B $3.53B $1.43B $597.18M $597.18M
-Long Term Debt $3.51B $3.53B $1.43B $597.18M $597.18M
Other Non-Current Liabilities $193.40M $209.82M $155.48M $150.82M $150.82M
Total Equity $6.26B $6.32B $6.21B $6.09B $6.09B
Stockholders' Equity $6.26B $6.32B $6.21B $6.09B $6.09B
Capital Stock $194,000.00 $194,000.00 $193,000.00 $192,000.00 $192,000.00
-Common Stock $194,000.00 $194,000.00 $193,000.00 $192,000.00 $192,000.00
Additional Paid-In Capital $6.09B $6.04B $5.97B $5.96B $5.96B
Retained Earnings $181.66M $304.50M $259.73M $154.21M $154.21M
Gains/Losses Not Affecting Retained Earnings -$4.01M -$8.78M -$4.24M -$13.47M -$13.47M
Other Equity Interests -$10.85M -$11.23M -$10.45M -$10.51M -$10.51M
-Available for Sale Securities – – – $492.24M $492.24M

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow $188.21M $168.11M $220.65M $827.99M $99.64M
Net cash flow from continuing operations $188.21M $168.11M $220.65M $827.99M $99.64M
Net Income from Continuing Operations -$122.83M $44.76M $105.53M $348.90M -$46.57M
Gain/Loss from Continuing Operations -$4.33M -$10.76M $6.71M $4.46M $4.22M
Depreciation & Depletion & Amortization $130.47M $97.64M $16.41M $79.56M $20.44M
Deferred Tax -$29.75M -$6.96M $9.22M $48.74M $613,000.00
Other Non-Cash Items $283.34M $21.67M $712,000.00 $219.17M $1.64M
Change in Working Capital -$137.41M -$54.39M $39.07M -$293.66M -$164.05M
-Change in Receivables -$14.43M -$38.85M -$7.16M -$228.05M -$120.68M
-Change in Inventory -$13.96M -$32.16M $44.49M -$116.93M -$18.13M
-Change in Payables and Accrued Expense -$78.94M $23.17M $3.10M $66.14M -$53.34M
-Change in Other Current Assets -$26.93M -$4.52M -$10.07M -$29.68M $35.12M
-Change in Other Current Liabilities -$3.16M -$2.04M $8.70M $14.87M -$7.02M
Net cash flow from investing -$306.90M -$5.10B $725.53M -$414.24M -$42.45M
Net Cash Flow from Continuing Investing Activities -$306.90M -$5.10B $725.53M -$414.24M -$42.45M
Net PPE Purchase and Sale -$28.29M -$28.82M -$20.92M -$103.04M -$40.72M
Net Intangibles Purchase and Sale $4.24M – – -$7.94M -$2.37M
Net Business Purchase and Sale -$277.88M – – -$285.19M $0.00
Net Investment Purchase and Sale $0.00 $0.00 $741.49M -$18.07M $641,000.00
Financing Cash Flow -$18.83M $2.74B $813.17M -$42.39M $3.16M
Net Cash Flow from Continuing Financing Activities -$18.83M $2.74B $813.17M -$42.39M $3.16M
Net Issuance Payments Of Debt -$15.00M $2.80B $850.00M $0.00 $0.00
Proceeds from Stock Option Exercised $0.00 – – $14.46M $6.75M
Net Other Financing Charges -$3.83M -$68.28M -$36.83M -$56.85M -$3.59M
Ending Cash Balance $736.01M $874.01M $3.07B $1.31B $1.31B
Net Change in Cash -$137.51M -$2.20B $1.76B $371.36M $60.35M
Beginning Cash Balance $874.01M $3.07B $1.31B $942.84M $1.25B
Effect of Exchange Rate Changes -$487,000.00 -$3.04M $1.41M -$2.52M $1.22M
Free Cash Flow $164.16M $133.86M $199.73M $717.02M $56.55M
Net Other Investing Changes – $0.00 $4.97M – –

Discussion

No comments yet — be the first to weigh in on BMRN.

Sign in to join the discussion.

Scroll to Top